Home / Intelligence / Case Studies / Improving Targeting Precision and Field Force Direction through AIML-based Patient Finding
Background
- A global rare disease company was looking to improve targeting precision and support field team effectiveness
- Traditional targeting was non-viable due to the small size of the patient populations, complex disease recognition and diagnosis, and restrictive therapy eligibility criteria
- Attempts by a prior analytics partner to use rule-based alerts failed, and even after two years, no new patients had been identified
- Given the small number of patients in each indication, every new start is high value, both for the lives of patients in need and for the commercial success of the therapies
Trinity’s Solution
- Create an AIML model that identifies clinically on-label patients—rather than simply patients with the disease
- ‘Learn’ from on-therapy patients to identify how patients present prior to therapy initiation and execute AIML models to flag patients based on the probability that they are candidates for treatment
- Deploy bifurcated notifications to both inside and field-based reps through ‘push’ alerts within the client’s CRM and enable ‘pull’ solutions to support call planning
- Success drivers include:
- Data acumen to evaluate and select source data
- Therapeutic area expertise
- Deep collaboration with Medical to refine and calibrate models
- AIML experience to optimize feature selection and approach
Project Outcomes
Designed and deployed AIML models for three indications in 8 weeks
Narrowed field team focus from >25,000 HCPs to ~1,000 highest priority HCPs
Identified 100 high probability targets within first 2 months of launch
At least 5 patients confirmed to be clinically on-label for therapy within first 2 months
First new patient enrolled within 5 weeks of initiating alerts
If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.
Related Intelligence
Webinars
Generative AI in Pharma – Five Years From Now
Available On Demand
Generative AI is having a transformative impact on the pharmaceutical industry. Drugmakers are partnering up with companies like Insilico Medicine, Exscientia, BenevolentAI, and more to leverage their respective generative AI-powered platforms and applying them across the pharma value chain: from accelerating drug discovery and optimizing clinical trials, to improving operational efficiencies and enabling personalized treatments […]
Watch Now
Webinars
The Future of Patient Finding
Available On Demand
Patient finding is more than a buzzword. Ready to challenge the status quo? With more data, advancements in AIML and greater access to insights, it is not surprising that patient finding is evolving. Many pharma organizations have deep-rooted ideas about what patient finding requires, but they often miss the opportunity to put the patient at […]
Watch Now
Blog
Can GenAI be Used to Improve Data Operations Efficiency?
The short answer is yes, by powering process automation with GenAI. It’s an approach that hasn’t received as much attention as other GenAI use cases within life sciences, but the results can be very powerful. To illustrate its power, we’ll examine a case study on identifying debarred healthcare professionals (HCPs). Why is it important to […]
Read More